The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM).
 
Xue Bai
Other Relationship - Bristol-Myers Squibb
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Immunocore
Research Funding - Bristol-Myers Squibb; Immunocore; Polaris; Xcovery
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Allison Betof Warner
Honoraria - LG Chem
Consulting or Advisory Role - BluePath Solutions; Iovance Biotherapeutics; Nanobiotix; Novartis; Shanghai Jo'Ann Medical Technology
Research Funding - Leap Therapeutics
 
Henry Quach
No Relationships to Disclose
 
Christopher G Cann
No Relationships to Disclose
 
Michael Zhang
No Relationships to Disclose
 
Lalit Pallan
No Relationships to Disclose
 
Catriona Harvey
No Relationships to Disclose
 
Lu Si
No Relationships to Disclose
 
Bixia Tang
No Relationships to Disclose
 
Chuanliang Cui
No Relationships to Disclose
 
Michelle S. Kim
No Relationships to Disclose
 
Tatyana Sharova
No Relationships to Disclose
 
Keith Flaherty
Stock and Other Ownership Interests - Apricity Health; Checkmate Pharmaceuticals; Clovis Oncology; FOGPharma; Fount Therapeutics; Kinnate Biopharma; Loxo; Oncoceutics; PIC Therapeutics; Shattuck Labs; Strata Oncology; Tvardi Therapeutics; X4 Pharma
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Array BioPharma; Asana Biosciences; Boston Biomedical; Bristol-Myers Squibb; Cell Medica; Debiopharm Group; FOGPharma; Genentech; Incyte; Lilly; Loxo; Merck; Neon Therapeutics; Novartis; Oncoceutics; Pierre Fabre; Roche; Sanofi; Shattuck Labs; Takeda; Tolero Pharmaceuticals; Tvardi Therapeutics; Verastem
Research Funding - Novartis; Sanofi
Travel, Accommodations, Expenses - Debiopharm Group; Pierre Fabre
 
Georgina V. Long
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Skyline Diagnostics; Specialised Therapeutics
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Ryan J. Sullivan
Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Viralytics (Inst)
 
Genevieve Marie Boland
Honoraria - Novartis; Takeda
Consulting or Advisory Role - Northwest Biotherapeutics
Research Funding - Olink; Palleon Pharmaceuticals; Takeda; Takeda
Other Relationship - Nektar
 
Douglas Buckner Johnson
Consulting or Advisory Role - Bristol-Myers Squibb; Catalyst Pharmaceuticals; Iovance Biotherapeutics; Janssen; Merck; Novartis; Oncosec
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere